GT Biopharma, a clinical-stage biopharmaceutical company based in Brisbane, California, focuses on immuno-oncology products using its TriKE NK cell engager platform, with its first candidate, GTB-3550, targeting cancer and HIV. Founded in 2013, the company employs two full-time staff and aims to enhance natural killer cell activity against diseases.